YUVEZZITM: the first and only combination eye drop approved to treat presbyopia.
Tenpoint Therapeutics secured $235M through a Series B Financing and Credit Facility.
Leading pharmaceutical executive strengthens leadership team as Tenpoint prepares for the potential commercial launch of BRIMOCHOL PF.
Get the most important news and business ideas for eyecare professionals every weekday from INVISION.
Advertisement
